@article{5882d0cabe79431a84ea7ca5519e5cfa,
title = "Nanoformulated zoledronic acid boosts the Vδ2T cell immunotherapeutic potential in colorectal cancer",
abstract = "Aminobisphosphonates, such as zoledronic acid (ZA), have shown potential in the treatment of different malignancies, including colorectal carcinoma (CRC). Yet, their clinical exploitation is limited by their high bone affinity and modest bioavailability. Here, ZA is encapsulated into the aqueous core of spherical polymeric nanoparticles (SPNs), whose size and architecture resemble that of biological vesicles. On Vδ2 T cells, derived from the peripheral blood of healthy donors and CRC patients, ZA-SPNs induce proliferation and trigger activation up to three orders of magnitude more efficiently than soluble ZA. These activated Vδ2 T cells kill CRC cells and tumor spheroids, and are able to migrate toward CRC cells in a microfluidic system. Notably, ZA-SPNs can also stimulate the proliferation of Vδ2 T cells from the tumor-infiltrating lymphocytes of CRC patients and boost their cytotoxic activity against patients{\textquoteright} autologous tumor organoids. These data represent a first step toward the use of nanoformulated ZA for immunotherapy in CRC patients. {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",
keywords = "Anti-tumor immunity, Colorectal carcinoma, Polymeric nanoconstruct, Vδ2 T cells, Zoledronic acid, zoledronic acid, Article, cancer immunotherapy, cell activation, cell migration, cell proliferation, cell viability, clinical article, colorectal cancer, colorectal cancer cell line, controlled study, cytotoxicity, drug effect, drug formulation, electrospray mass spectrometry, encapsulation, ex vivo study, high performance liquid chromatography, human, human cell, human tissue, immunofluorescence, in vitro study, microfluidics, particle size, physical chemistry, scanning electron microscopy, T lymphocyte, tumor associated leukocyte, tumor spheroid",
author = "{Di Mascolo}, D. and S. Varesano and R. Benelli and H. Mollica and A. Salis and M.R. Zocchi and P. Decuzzi and A. Poggi",
note = "Cited By :4 Export Date: 11 March 2021 Correspondence Address: Poggi, A.; Molecular Oncology and Angiogenesis Unit, Italy; email: alessandro.poggi@hsanmartino.it Chemicals/CAS: zoledronic acid, 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7 Manufacturers: Selleck, Italy Funding details: ERC616695 Funding details: IG 17664 Funding details: Compagnia di San Paolo Funding details: European Research Council, ERC Funding details: Ministero della Salute Funding details: Agenzia Italiana del Farmaco, Ministero della Salute, AIFA, AIRCIG 17664 Funding details: Seventh Framework Programme, FP7 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 5xmille 2014, IG 21648 Funding text 1: The authors thank N. Ferrari for the GFP + SW480 CRC cell line; C. Malfatto for separating PBMCs from CRC patients; D. La Torre for providing us venous blood samples of CRC patients; S. Scabini, E. Romairone, L. Mastracci, and F. Grillo for providing us the tumor specimens of CRC patients; F. Tosetti and A. Profumo for help in preparation and evaluation of for IPP content. A.P. acknowledges the partial support by the Italian Association for Cancer Research (AIRC) IG 21648, 5xmille 2014, 5xmille2015 from Ministero della Salute and Ricerca Corrente 2018?2021. P.D. acknowledges the partial support by the Italian Association for Cancer Research AIRCIG 17664; the Fondazione San Paolo project ?Ligurian Alliance for Nanomedicine against cancer?, and the European Union?s Seventh Framework Programme (FP7/2007-2013) ERC616695. Funding text 2: Acknowledgments: The authors thank N. Ferrari for the GFP + SW480 CRC cell line; C. Malfatto for separating PBMCs from CRC patients; D. La Torre for providing us venous blood samples of CRC patients; S. Scabini, E. Romairone, L. Mastracci, and F. Grillo for providing us the tumor specimens of CRC patients; F. Tosetti and A. Profumo for help in preparation and evaluation of for IPP content. A.P. acknowledges the partial support by the Italian Association for Cancer Research (AIRC) IG 21648, 5xmille 2014, 5xmille2015 from Ministero della Salute and Ricerca Corrente 2018–2021. P.D. acknowledges the partial support by the Italian Association for Cancer Research AIRC IG 17664; the Fondazione San Paolo project “Ligurian Alliance for Nanomedicine against cancer”, and the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013) ERC 616695.",
year = "2020",
doi = "10.3390/cancers12010104",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "1",
}